Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIIItrials
British Journal of Dermatology2020Vol. 183(2), pp. 242–255
Citations Over TimeTop 1% of 2020 papers
Eric L. Simpson, J.‐P. Lacour, Lynda Spelman, Ricardo Galimberti, Lawrence F. Eichenfield, Robert Bissonnette, Brett King, Jacob P. Thyssen, Jonathan I. Silverberg, Thomas Bieber, Kenji Kabashima, Yuichiro Tsunemi, Antonio Costanzo, Emma Guttman‐Yassky, Lisa A. Beck, Jonathan Janes, Amy M. DeLozier, Margaret Gamalo, Dennis Brinker, T. Cardillo, Fabio P. Nunes, Amy S. Paller, Andreas Wollenberg, Kristian Reich
Abstract
Baricitinib improved clinical signs and symptoms in patients with moderate-to-severe AD within 16 weeks of treatment and induced rapid reduction of itch. The safety profile remained consistent with prior findings from baricitinib clinical development in AD, with no new safety concerns.
Related Papers
- → Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).(2021)76 cited
- → Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer(2007)26 cited
- → Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated MGMT gene promoter: RACTAC, a phase II multicenter trial(2023)14 cited
- → 265O Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial(2020)10 cited
- → A Systemic Review of Dupilumab Efficacy and Safety by Phenotypic Variations of Atopic Dermatitis(2021)